Transplant Rejection Clinical Trial
Official title:
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020
Up to approximately 2 years ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04615221 -
Immunological Mechanisms of Rejection in Uterine Transplantation
|
N/A | |
| Recruiting |
NCT03984747 -
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
|
||
| Completed |
NCT04046549 -
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
|
Phase 2 | |
| Completed |
NCT01338779 -
Study of Tolerant Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT03582436 -
Rejection Diagnosis in Kidney Transplants Patients
|
||
| Completed |
NCT01766050 -
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
|
Phase 4 | |
| Completed |
NCT01236378 -
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
|
Phase 1 |